Phase 2 N=208 Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia
Pre-Eclampsia
Primary: Change in Pulsatility Index (PI) — -0.56; -0.53; -0.43; -0.88 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
Myelofibrosis
Primary: Most Common Treatment Related Adverse Events — 1; 1; 2; 1 participants
Phase 2 N=161 A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
Diabetic Gastroparesis · Idiopathic Gastroparesis
Primary: Change From Baseline of Nausea Severity Score — -3.55; -3.65; -3.43; -2.83 units on a scale — p=0.1350
Phase 2 N=19 Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percentage of Patients in Non-progression at 2 Months — 14.3 percentage of participants
Phase 2 N=57 A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Sarcoma · Liposarcoma · Leiomyosarcoma
Primary: 12-week Progression Free Survival (PFS) — 69.6; 36.8; 52.6 percentage of participants
Phase 2 N=139 Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Huntington Chorea
Primary: Change in Total Maximal Chorea (TMC) Score of the UHDRS® for Subjects Not Taking Neuroleptics During the Trial (mITT - N=122) — -2.19; -2.42; -3.46 units on a scale…
Phase 2 N=4 Transcranial Photobiomodulation for Executive Function in Bipolar Disorder
Bipolar Disorder
Primary: Test the Effect of Transcranial Photobiomodulation (tPBM) on Cerebral Blood Flow (CBF) — 6611.645; 6666.398 A.U.
Phase 2 N=394 Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
Coronavirus Disease 2019
Primary: All-cause Mortality at Day 28 — 52; 27; 23; 207 Participants
Phase 2 N=38 Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
Acute Malaria
Primary: Cohort A: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs — 9; 0; 1 Participants
Phase 2 N=219 Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis
Cryptococcal Meningitis
Primary: Early Fungicidal Activity — 0.39; 0.28 log10 CFU/mL/day
Phase 2 N=201 Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Glaucoma Open-Angle Primary · Ocular Hypertension
Primary: Efficacy as Assessed by Change in Intraocular Pressure — -6.3; -6.3; -5.9; -7.0 mmHg
Phase 2 N=46 Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
Non-Small Cell Lung Cancer · Solid Tumor
Primary: Overall Response Rate — 50.0; 33.3; 7.9; 0 percentage of participants
Phase 2 N=55 Effects of Pioglitazone on Stress Reactivity and Alcohol Craving
Alcohol Use Disorder
Primary: Change in Stress-reactivity as Assessed by Heart Rate Change During the Cold Pressor Task (CPT) — 5.138; 12.154 beats per minutes (bpm)
Phase 2 N=29 A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Melanoma (Skin) · Cutaneous Melanoma · Adult Disease
Primary: Monotherapy Dose Expansion: Objective Response Rate (ORR) as Defined by RECIST v1.1 — 0; 0 Participants
Phase 2 N=34 Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Leukemia · Myelodysplastic Syndromes · Childhood Acute Myeloid Leukemia in Remission
Primary: Incidence of Engraftment — 100; 93; 100 Percentage of participants